Carmed Pharmaceuticals, a science-driven company specializing in standardized carvacrol-based formulations, is expanding into the United States market under the leadership of its founder, Mustafa Can. The expansion follows years of research and formulation development led by Can, who established the company in 2019 after several years of prior scientific exploration focused on standardized botanical bioactives and mechanism-based product design.
This market entry represents a significant development in the botanical supplements industry, where scientific validation and quality control remain critical challenges. Carmed's approach integrates traditional botanical knowledge with modern pharmaceutical methodology to create formulations designed to support immune resilience, cellular health, and overall physiological balance. The company operates with a research-driven framework that includes in vitro analysis, mechanism-based evaluation, formulation standardization, and structured quality control processes.
Founder Mustafa Can built his career in the maritime industry as a ship master before transitioning to botanical research about a decade ago. Without formal scientific training, Can immersed himself in self-directed study, reviewing thousands of scientific publications and exploring the chemistry of botanical compounds used in traditional medicine. Today, the company operates with a core team of approximately 25 full-time professionals and collaborates with a broader network of physicians, researchers, laboratories, and medical institutions involved in formulation development and scientific evaluation of bioactive compounds.
"From the beginning, our objective was to approach botanical formulations with scientific discipline," said Can. "We wanted to focus on standardization, reproducibility, and analytical validation so that formulations are developed with a clear and consistent scientific rationale." Can added that Carmed's long-term strategy prioritizes continued research and product development, with significant resources reinvested into scientific investigation and formulation development.
As part of its U.S. expansion, Carmed Pharmaceuticals plans to introduce several flagship formulations including Vacrol® Kids Spray for children ages 4–11, S-Mix® for immune function support, Vacrol® Capsule for microbial balance, Vacrol-M® Capsule for respiratory wellness, and Omevaq-3® for cellular energy metabolism. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. All Carmed products are manufactured in facilities operating in accordance with Good Manufacturing Practice (GMP) principles and relevant regulatory standards.
Carmed's research efforts are supported by collaborations with academic institutions, laboratories, and medical researchers. In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based formulations and multicomponent botanical interactions. The company emphasizes that such research reflects scientific investigation into botanical bioactivity and formulation design and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
The U.S. expansion comes at a time when consumers increasingly seek scientifically validated wellness products with transparent manufacturing processes. Carmed states its strategy is focused on regulatory alignment, scientific credibility, and long-term positioning within the preventive wellness sector. According to Can, Carmed's development strategy focuses on combining botanical bioactives in standardized formulations designed to interact across multiple biological pathways. "Our formulations are built on what we describe as rational synergy," Can said. "Rather than relying on isolated ingredients, we design standardized combinations selected to work together in a consistent and reproducible manner."
Distribution timelines and retail availability for the United States will be announced in the coming months. The company maintains an online presence through its website and social media channels. As the botanical supplements market continues to grow, Carmed's emphasis on scientific validation and quality control could influence industry standards and consumer expectations for evidence-based wellness products.
